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Introductiona phosphorothioate (PS) backbone, A7, 12258, 12259 have a mixed phosphodiester and PS backbone, A7 contains an inverted thymine base at the 3' end and A10 and A11 have a complete PS backbone, with a 2'Omethyl modification of the ribose in the first four and last four bases. Mixed backbone oligos retain much of the nuclease resistance of PS oligos, with reduction in toxicity [26] . Finally, the A10 oligo used for much of the in vitro and all of the in vivo trials has a PS backbone, with the first four and last four bases 2'O-methyl modified RNA bases. This structure lends itself to RNaseH-mediated degradation of target RNA, with greater in vivo bioavailability [27] . Control oligos A11 and 11899 are the reverse sequences of A10 and 12259, respectively, with oligo 1582 used as a nonspecific control for the rest of the experiments. Oligos were selected to avoid dimers and stem loop structures as well as CpG dinucleotides [28] . A4-A10 included the TCCC tetranucleotide motif shown to increase probability of RNaseH-mediated RNA destruction [29] . After synthesis, oligos were cleared of contaminants by desalting and gel purification (A1-A6), HPLC (A7, 12258, 12259), and ion exchange HPLC (A10, A11). Oligo synthesis was performed by OligosEtc (A1-A7, Wilsonville, OR), Sequitur (11899, 12258, 12259, Natick, MA), and Integrated DNA Technologies (A10, A11, Coralville IA).
Oligonucleotide transfection and analysis of MBD2 mRNA and MBD2 protein-A549 human non-small cell lung carcinoma (ATCC# CCL-185), HCT116 human colon carcinoma cells (ATCC# CCL-247), MRHF human foreskin fibroblasts (Biowhittaker, Wakersville, MD) were cultured free of antibiotics in the recommended media to facilitate oligo transfection and plated at a density of 3x10 5 per 10 cm plate 24 to 48 hours before transfection. Oligos were added to cells at a final concentration of 20, 50 or 200 nM using either 6.25 ml/ml Lipofectin for A549 cells or 4 ml/ml Lipofectamine (Invitrogen, Carlsbad CA) for HCT116 cells as lipid carriers. Transfection was repeated after 24 hours, cells were harvested with TRIzol (Invitrogen), total RNA was prepared according to manufacturer's recommendation and was subjected to gel electrophoresis, Northern blot transfer onto Hybond-N+ membrane (Amersham pharmacia biotech) according to the manufacturer's recommendations and hybridization with a 1.3 kb MBD2b cDNA probe [11] in a 10 ml hybridization solution containing 7% SDS, 0.5 M sodium phosphate pH 6.8, and 1 mM EDTA at 68 o C for 4 hours. Following washing and exposure to a phosphor-imaging plate, the membrane was stripped and hybridized to a 32 P-labelled 18S rRNA probe as previously described [30] . The signals for MBD2 and 18S were quantified by densitometry and the intensity of the MBD2 signal was normalized to the signal obtained for 18S. A549 cells were harvested after a single treatment with oligo, nuclear extracts prepared as previously described [31] were resolved by electrophoresis, and membranes were probed with 1:200 dilution of a monoclonal anti-MBD2 antibody (Imgenex, San Diego, CA) in 0.05M Tris-0.2M NaCl, pH 7.6 (TBS) containing 0.5% Tween 20, and 5% milk overnight at 4 o C. The blot was then reacted with a secondary antimouse monoclonal antibody at a 1:20,000 dilution and the band developed with the ECL kit from Amersham pharmacia biotech. To control for equal loading, b-actin Western blots were performed using a 1:5000 dilution of anti-b-actin monoclonal antibody (Sigma cat no A-5316), followed by mouse secondary antibody as just described for MBD2. Primers used for RT-PCR analysis of DNMT1 and the sequences of DNMT1 antisense ODN MG88 and the mismatch control MG208 were previously described [33] .
Anchorage -independent and -dependent growth analyses To determine anchorage-independent growth on soft agar, 3000 live cells treated with a single dose of antisense or control oligos for 24 hours were seeded into soft agar and plated in triplicate in a six well plate for 21 days as previously described [34] . The number of colonies (>10 cells per colony) in five random fields (40X) per well, throughout all planes of the triplicate wells, was counted after 21 days under microscopy.
For anchorage-dependent cell growth experiments, A549 and HCT116, cells were plated at the concentration of 50,000 cells/dish. After 24 hours, cells were treated with 200 nM of control or MBD2 antisense oligonucleotide. Treatments were repeated after 24 h and cells were harvested 24, 48 and 72 h after the second treatment (Day 1, Day 2, Day 3, respectively). To determine cell cycle kinetics, the cells were fixed for 18 h in 70% ethanol at 4°C, and treated with propidium iodide to label DNA [35] . Twenty thousand cells were sorted in triplicate for DNA content in a Becton Dickinson (Franklin Lakes, NJ) FACScan cell sorter and data were acquired by the LYSIS II program [36] .
Analysis of hematological and biochemical parameters
Analysis of hematological values and serum biochemical parameters was performed by McGill University Animal Resources centre Diagnostic and research support service using standard procedures.
Results

Selection of specific MBD2 antisense oligonucleotides
To test the hypothesis that pharmacological inhibition of MBD2 is in principle a novel approach to human anticancer therapeutics, we designed antisense oligonucleotides that could be administered as pharmacological agents in vivo using human tumors implanted in nude mice as a model. The general rules that guided our design of antisense oligonucleotides are described in the materials and methods. Following initial screening of several antisense oligos to human MBD2 cDNA ( Figure 1A ) showing varying degrees of MBD2 mRNA inhibition at the 200 nM concentration relative to a control oligonucleotide, we selected, A7 which exhibited up to 90% inhibition ( Figure 1B ). The A10 sequence is highly conserved between the mouse and the human and there is only one base mismatch between the human and mouse sequence. A7 was further modified by positioning a 2'O-methyl modification on the ribose of the first and last 4 nucleotides and was designated A10. This structure enables RNaseH-mediated degradation of target RNA, with greater in vivo bioavailability [27] . A11, a reverse sequence of A10, served as a control. Specific and dose-dependent inhibition of target MBD2 mRNA was observed in both A549 and HCT116 cells treated with A10 ( Figure 1C ) in comparison with the A11 control. Dose-dependent knock-down of MBD2 protein in A549 cells was confirmed by a Western blot analysis ( Figure 1D ).
MBD2 antisense inhibitors reduce anchorage independent growth of human cancer cell lines
We first tested the hypothesis that MBD2 antisense oligonucleotides inhibit anchorage independent growth of human cells on soft agar, which is an indicator of the tumorigenic potential of cancer cells [37] . Both 12259 and A10 MBD2 antisense oligonucleotides inhibited the anchorage-independent growth of A549 cells in comparison with the 11899 and A11 reverse controls (Figure 2A and 2B), in a dose-dependent manner. 12259 is somewhat less effective than A10 in its inhibition of MBD2 mRNA ( Figure 1B ) as well as anchorage independent growth (Figure 2A ), we therefore focused on A10. A10 also inhibited anchorage-independent growth of HCT116 cells using a 200 nM dose suggesting that this inhibition is not unique to A549 cells ( Figure 2B ). The fact that the same result was observed with two independent sets of antisense oligonucleotides that bear different backbone modifications (12259 and A10) supports the hypothesis that inhibition of anchorage independent growth of A549 cells is sequence specific and is a consequence of the knockdown of MBD2 rather than some idiosyncrasies of the specific antisense oligonucleotide.
Inhibition of tumor implantation in vivo by MBD2 antisense
Since MBD2 antisense treatment prohibited anchorage-independent growth of both colon-and lung-derived tumor cells, we determined whether such a treatment could inhibit the ability of tumor cells to implant in vivo.
One property of tumor cells is their ability to implant as xenoplants in vivo as well as migrate and metastasize into non-cognate tissues. To differentiate between the role of MBD2 in tumor growth in vivo and the implantation process per se, we first treated the cells with MBD2 antisense in vitro and then implanted them in vivo. The animals were not treated with oligonucleotides. Naïve cells of both A549 lung cancer and HCT116 colorectal cancer lines showed rapid tumor growth when implanted in Balb/c nude mice (data not shown). 2.5x10 6 of A549 or HCT116 cells (8 mice per treatment group) were treated for 48 hours in vitro with either 200 nM of A10 or the control A11 oligonucleotide and were injected subcutaneously into the right flank of female BALB/cAnNCrl-nuBR nude mice (5-6 weeks old, Charles River). Whereas palpable tumors formed rapidly from A11 control treated cells, this process was slowed in A10 treated cells ( Figure 3A, B) . Effects on tumor burden were even more dramatic for HCT116 cells, with all 6 of the A11 group showing measurable tumors, but only 1 of 9 of the antisense group. Growth rate was reduced for A10 treated cells, as was final tumor mass (54% for A549, 95% for HCT116, Figure 3A /B, insets). These results are similar to the soft agar experiment where pretreatment of the cells inhibits their ability to grow on soft agar even in the absence of any further treatment suggesting that the seeding of cancer cells in an anchorage deprived environment requires MBD2. Since the cells are treated only once in vitro, and are not further treated in vivo, our results are consistent with the hypothesis that MBD2 is required for the first stage of implantation of tumors in a foreign environment in vivo. HCT116 cells are more sensitive to treatment in vitro with A10 than A549 cells. We do not know whether this is caused by the somewhat more effective inhibition of MBD2 mRNA by A10 in HCT116 cells ( Figure 1C ) or whether HCT116 and A549 cells have different requirements for MBD2 for their ability to implant in vivo and to grow in an anchorage independent manner.
MBD2 antisense inhibits tumor growth in vivo
We then determined whether pharmacological administration of A10 inhibits the growth of preimplanted naive human cancer cells in nude mice. 2.5x10 6 naïve A549 or HCT116 cells were injected subcutaneously into BALB/cAnNCrl-nuBR nude mice. Three days post implantation, when solid tumors were already visible, the mice (8 per group) were injected via tail vein 3 times per week with control or antisense oligo, at doses of 2, 4, or 8 mg/kg dissolved in 100 ml sterile PBS. The mice were monitored for tumor growth 3 times per week, and tumor volume was estimated by using V = (L x W 2 ) x 0.5, where L is the length and W is the width of a xenograft [38] and observed for cachexia, lethargy, lesions and other signs of toxicity. The mice were sacrificed after 24 or 29 d by exsanguination and their blood was analyzed for liver and kidney function as well as hemocyotology. A549 cells were more sensitive to systemic antisense treatment than in vitro treatment. All 3 doses of A10 showed significant inhibitory effects on tumor growth (Fig 3C) , with complete tumor regression seen in 2 mice dosed with 8 mg/kg (Fig 3E) . One mouse in this same antisense group died after 17 days postimplantation but the cause of death is unclear. Numbers of tumor-free mice for 2, 4, and 8 mg/kg groups were 5/8, 7/8, 7/8 for A10, and 1/8, 1/8 and 0/8 for A11 treatments. The mice were sacrificed after 29 days and the tumors were weighed ( Figure 4A ) and photographed ( Figure 4C ). Thus, MBD2 antisense treatment essentially eliminated the ability of A549 cells to grow as tumor xenoplants in nude mice. MBD2 antisense inhibition of tumor growth is not limited to human lung non-small cell carcinoma since A10 also reduced tumor growth of HCT116 colon cancer cells in nude mice (Fig 3D) . HCT116 cells appeared to be extremely sensitive to reductions in MBD2 as indicated by the complete regression of tumors in some mice at each dose concentration ( Figure 3F ). However, the dose required for maximal effect on HCT 116 (8mg/kg) is higher than the dose required for A549 cells (maximal effect is achieved already at 2 mg/kg). Numbers of tumor-free mice for 2, 4, and 8 mg/kg groups were 5/8, 7/8, 8/8 for A10, and 1/8, 1/6 and 1/8 for A11 treatments. Two mice in the A11 4 mg/kg group died of cachexia, perhaps due to tumor burden. None of the antisense treated mice implanted with HCT116 cells died before sacrifice. A dose dependent reduction in tumor mass with A10 antisense treatment was observed when the tumor mass was determined following sacrifice of the animals (Figure 4 B and D) . In summary, our data suggests that MBD2 is necessary for tumor growth in vivo in addition to being required for tumor implantation.
MBD2 antisense treatment does not inhibit cell growth and viability of either normal or cancer cells under
anchorage dependent conditions-As nonspecific effects on normal cell viability and growth often hinder therapeutic potential of many anticancer agents, we investigated the impact of A10 on cell proliferation of normal human cells. Antisense to MBD2 proved to be relatively innocuous to the growth of normal MRHF human foreskin fibroblasts. Dosing regimens of A10 for the same time period of 48h that proved inhibitory to cancer cell colony formation and xenograft growth (Fig. 2 and 3A) had little effect on contact-dependent growth of MRHF cells relative to A11 or mock treatment (Fig. 5A ). Cell viability, as measured by trypan blue exclusion, was approximately 100% over Day 1 to Day 3 (data not shown). We also determined the effect that MBD2 antisense might have on A549 and HCT116 cell lines (Fig. 5B, C) . Surprisingly, in light of the strong inhibitory effects on tumorigenicity in these cells, A10 had minimal impact on the ability of the tumor cells to grow on a semi-solid support (Fig. 5B, C) . For A549 and HCT116 cells, viability remained >90% for A10, A11, and mock treatment groups with no differences between groups. There was no indication of cell death or apoptosis. Finally, we treated A549 cells with 200 nM of A10 or A11 and harvested the cells to look at progression through the cell cycle. FACS analysis revealed that cohorts of cells remained unchanged throughout the cell cycle (Fig. 5D ). These data indicate that the oligos are neither cytotoxic nor cytostatic for growing cells (tumor or nonneoplastic), and that they do not induce apoptotic or necrotic mechanisms. The fact that AS10 treatment does not impact either growth or cell cycle kinetics excludes the possibility that the antisense DNA acts by an interferon mediated pathway, which should result in cell cycle arrest [39, 40] .
To demonstrate that A10 exhibits a gene specific effect rather than a non specific "double stranded RNA-DNA" effect on tumor cells, we compared the effect that A10 has on growth of A549 cells to the effects of MG88 a well-characterized antisense inhibitor of DNMT1 (Fig. 5E) on the same cells. MG88 is well documented to inhibit tumorigenesis in vitro similar to AS10 [41]. However in difference from AS 10, MG88 has a dramatic effect on cell growth after 48h treatment (Fig. 5F ). This difference in the effects of these two antisense oligonucleotides on cell growth parameters highlights the fundamental difference between DNMT1 and MBD2 antisense inhibitors supporting the conclusion that MBD2 antisense effects are gene specific. It also highlights the uniqueness of MBD2 inhibitors amongst anticancer targets, which usually target the cell cycle machinery like MG88. Our data showing that MBD2 knock down has no effect on cell growth agrees with the normal development, viability and fertility of mbd2-/-mice [24] . In summary, MBD2 has a distinct and unique role in tumorigenesis in that it is required for tumorigenesis in vivo and in vitro but not for cell growth.
Since the A10 antisense is highly complementary to the murine mbd2 mRNA sequence; there is only one base mismatch between the human and mouse sequence at this position, we determined whether A10 had a specific toxic effect on proliferating tissues in vivo. We first monitored animal weight throughout the experiment. The results shown in Figure 6 demonstrate that MBD2 antisense oligonucleotides had no effect on animal weight at any of the concentration used in this experiment. Blood samples were obtained from treated mice at sacrifice and screened for various markers of in vivo toxicity (Table 1) . Throughout the various dosing concentrations, no differences were seen between A10 and A11 for hematological measurements, indicating that the blood cell precursors which are often sensitive to chemotherapeutic regimens were largely unaffected by serial dosing of antisense oligos. Platelet numbers were, however, increased above normal levels, regardless of treatment or dose; this is probably caused by the multiple tail vein injections. Urea, creatinine, aspartate aminotransferase (AST) and alanine aminotransferase (ALT), indices of liver, muscle, and kidney damage, similarly showed no negative effects from in vivo treatment. Swelling of the inguinal lymph nodes was a nonspecific but dose-dependent effect of the oligos that occurred in several mice treated with 4 or 8 mg/kg.
Although the almost identity of AS10 target and the mouse mbd2 mRNA sequence should have resulted in knock down of the murine message, it is not clear whether the lack of effect is a consequence of limited delivery or the complete innocuous consequences of MBD2 knock down. It is hard to determine the extent of knock down of MBD2 in living tissues since the tissue might include different cell types with different permeability for ODNs. An acute treatment of mice with either AS10 or AS11 as a control revealed a bimodal response in MBD2 mRNA levels (Fig 6B) . Two out of the five treated mice had reduced MBD2 mRNA in the kidney and three out of the five treated mice had a reduced MBD2 mRNA in the lungs relative to AS11 treated controls. The complexity of assessing the significance of these reductions in living organs precludes us from arriving at a definite answer. Further extensive experiments are required to define the extent of MBD2 inhibition in normal tissues. However taken together with the previously published knock out experiment, which suggests that MBD2 is not required for normal growth and viability our data supports the conclusion that the ODN antisense treatment does not result in additional unexpected toxicity to normal tissues.
In summary, MBD2 antisense knockdown has a distinct effect on tumorigenesis in vivo and in vitro but does not affect proliferation of normal and cancer cells.
DISCUSSION
This paper shows that pharmacological inhibition of MBD2 blocks the growth of human cancer cells in mice in vivo, provides a proof of principle for MBD2 as anticancer target and describes the selection of a second generation MBD2 antisense oligonucleotide as a candidate anticancer agent. It has been previously demonstrated that modified-backbone antisense molecules can distribute widely within the body [27, 42] following tail vein injection, and are stable for several days. In this paper we show that tumorigenic indices both in vitro and in vivo are reduced by MBD2 antisense oligos, which inhibit MBD2 expression in the nanomolar range (Figure 1 ). Parenteral injection of small antisense molecules results in significant tumor growth retardation and even complete absence of tumors at the 8 mg/kg concentration with a minimal degree of adverse effects on blood and liver cells. One important question that should be addressed in future experiments is whether it is necessary to treat the mice three times per week with high dose of oligo or whether short treatment will suffice and thus any possible side effects can be avoided? It is interesting to note that a short treatment for 48h in vitro was sufficient to block the ability of HCT116 cells to grow after implantation in vivo (Fig. 3A) .
The fact that pretreatment of the cells with MBD2 antisense inhibits their ability to grow on soft agar ( Figure  2 ) or implant in nude mice ( Figure 3A and B) , even though they are not treated any further, either during their soft agar growth or their growth as xenoplants in vivo, shows that a certain level of MBD2 expression is required for the initial steps of implantation of tumor cells in vivo. In addition, MBD2 is required to enable the tumors, once implanted, to continue and survive in a non cognate environment, as indicated by the inhibition of tumor growth by antisense treatment three days after implantation (Figure 3 B, C) and the regression of implanted tumors following MBD2 antisense treatment (Figure 3 E, F) . It is unclear yet whether MBD2 controls different sets of genes required for implantation and those required for continuous growth of tumors in vivo or whether the same proteins are involved in both processes. Genetic knock out data suggested that MBD2 protein was required for tumorigenesis in the mouse [24] but it did not address the question of whether inhibition of MBD2 can reverse the growth of already established tumors, which is critical if MBD2 inhibitors are to be used as anticancer therapeutics. The data presented here supports the hypothesis that MBD2 inhibitors could serve as anticancer therapeutics. It also illustrates that MBD2 is required for tumorigenesis of human cancer and is not an idiosyncrasy of the mouse system. MBD2 antisense treatment in vitro does not result in overt toxicity against normal proliferating cell nor does it inhibit the cell cycle of tumor cell lines supporting the hypothesis that MBD2 inhibition has a specific anticancer effect. This is in accordance with previously published data using either genetic knock out of mbd2 gene [25] or gene therapy antisense knockdowns of MBD2 [23] . The lack of toxicity and normal cell growth inhibition for our agents indicates that MBD2 antisense oligonucleotides show potential as anticancer agents and that MBD2 is a promising and unique anticancer target since many anticancer agents either damage cell division or target cell cycle regulatory mechanisms resulting inevitably in toxic effects on normally cycling cells.
The unique role of MBD2 in cancer remains to be fully defined, and the genes controlled by MBD2 that are required for tumorigenesis in either the mouse knock out model recently described [24] or in our model are yet unknown. It is tempting to speculate that MBD2 controls the function of genes, which are specifically required to bypass normal growth inhibitory signals that are elicited when a cell is found in either anchorage independent growth conditions or in a non-cognate environment in vivo. These functions might not be required for normal cell growth or normal development. The tools developed in this study will allow future experiments aimed at addressing the specific role of MBD2 in tumorigenesis.
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Fournel, M., Sapieha, P., Beaulieu, N., Besterman, J.M. Fig. 4 (A-A549 experiment; B-HCT116 experiment) were weighed at the indicated time points and the average weight per treatment group is indicated in grams +/-SEM (B). C. 5 animals were injected with either A10 or A11 at a dose of 8mg/kg at an interval of 48 h, were sacrificed 48 h after the second injection and RNA was prepared from the lungs and kidneys. The RNA was subjected to a Northern blot analysis and hybridization with either an MBD2 or an18s rRNA probe as indicated. D. The intensities of the signals for MBD2 mRNA normalized for 18srRNA were determined by densitometry. The horizontal line indicates the average per group. Table 1 . MBD2 antisense is nontoxic in vivo. Blood samples were drawn from xenograft mice at sacrifice and analyzed. RBC -red blood cells, WBC -white blood cells, AST -aspartate aminotransferase and ALTalanine aminotransferase. Errors are SEM for 14-16 mice per group.
